Sold as Oxilan-300, Oxilan-350. Every FDA application for this active ingredient.
As of Nov 13, 2026, FDA lists 1 application for Ioxilan (sold as Oxilan-300, Oxilan-350), first approved Dec 21, 1995, with 0 new uses approved and 0 published complete response letters.
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Dec 21, 1995 | Oxilan-300, Oxilan-350NDA 20316 ยท New molecular entity | Guerbet | 13 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number. Drugs@FDA
